Valproic acid
- Generic Name
- Valproic acid
- Brand Names
- Depakene, Depakote, Epival
- Drug Type
- Small Molecule
- Chemical Formula
- C8H16O2
- CAS Number
- 99-66-1
- Unique Ingredient Identifier
- 614OI1Z5WI
- Background
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects o...
- Indication
Indicated for:
1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures.
2) Adjunctive therapy in the management of multiple seizure types that include absence seizures.
3) Prophylaxis of migraine headaches.
4) Acute management of mania associated with bipolar disorder.
...
- Associated Conditions
- Bipolar Disorder (BD), Complex Partial Seizure Disorder, Depressive Episodes, Migraine, Petit Mal Epilepsy, Seizure, multiple types, Acute Manic episode
- Associated Therapies
- -
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
- First Posted Date
- 2010-08-16
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT01182285
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Seizures Post Intracerebral Hemorrhage
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Wolfson Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT01115959
Safety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder
- Conditions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2010-02-24
- Lead Sponsor
- Lawson, William B., M.D., PhD, DFAPA
- Target Recruit Count
- 50
- Registration Number
- NCT01075126
- Locations
- 🇺🇸
Howard University Hospital, Washington, District of Columbia, United States
A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy
- Conditions
- Interventions
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 140
- Registration Number
- NCT01030094
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Auxilio Mutuo Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT01016990
- Locations
- 🇵🇷
Centro de Cancer del Hospital Auxilio Mutuo, San Juan, Puerto Rico
Adjuvant Valproate for High Grade Sarcomas
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 7
- Registration Number
- NCT01010958
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 31
- Registration Number
- NCT01007695
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 38
- Registration Number
- NCT00879437
- Locations
- 🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2009-05-20
- Lead Sponsor
- Desitin Arzneimittel GmbH
- Target Recruit Count
- 82
- Registration Number
- NCT00870688
Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2016-08-31
- Lead Sponsor
- University Hospital Freiburg
- Target Recruit Count
- 204
- Registration Number
- NCT00867672
- Locations
- 🇩🇪
Vivantes Klinikum Neukölln, Berlin, Germany
🇩🇪Augusta-Kranken-Anstalt gGmbH, Bochum, Germany
🇩🇪Klinikum der Technischen Universität Aachen, Aachen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.